Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions

Cancer Cytopathology

Volumn 124, Issue 5, 2016, Pages 317-323

  Zhou, Haijun ^a   Mody, Roxanne R ^b   Luna, Eric ^c   Armylagos, Donna ^c   Xu, Jiaqiong ^d   Schwartz, Mary R ^a   Mody, Dina R ^a,e   Ge, Yimin ^a,e  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b St Joseph's Hospital   (United States)

^c Bioreference Laboratory   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

College of American Pathologists (CAP) benchmark; cotesting; high grade cervicovaginal lesion; human papillomavirus (HPV) test; Papanicolaou (Pap) test

Indexed keywords

ADENOCARCINOMA IN SITU; ADOLESCENT; ADULT; AGED; ARTICLE; CYTODIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VAGINA SMEAR KIT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FOOD AND DRUG ADMINISTRATION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VAGINAL NEOPLASMS; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

VIRUS DNA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84968560966     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21687     Document Type: Article

References (28)

1. Schiffman M, Castle PE,. The promise of global cervical-cancer prevention. N Engl J Med. 2005; 353: 2101-2104.
2. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014.
3. Moyer VA,. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156: 880-891.
4. Saslow D, Solomon D, Lawson HW, et al., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137: 516-542.
5. Gyllensten U, Gustavsson I, Lindell M, Wilander E,. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012; 125: 343-345.
6. Leinonen MK, Nieminen P, Lonnberg S, et al., Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012; 345: e7789.
7. Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M,. The HPV test has similar sensitivity but more overdiagnosis than the Pap test-a randomised health services study on cervical cancer screening in Finland. Int J Cancer. 2013; 132: 2141-2147.
8. Ogilvie GS, Krajden M, van Niekerk DJ, et al., Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL study. Br J Cancer. 2012; 107: 1917-1924.
9. Rijkaart DC, Berkhof J, van Kemenade FJ, et al., HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer. 2012; 106: 975-981.
10. Ronco G, Dillner J, Elfstrom KM, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383: 524-532.
11. Huh WK, Ault KA, Chelmow D, et al., Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015; 125: 330-337.
12. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL,. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012; 206: 46.e1-46.e11.
13. Austin RM, Zhao C,. Is 58% sensitivity for detection of cervical intraepithelial neoplasia 3 and invasive cervical cancer optimal for cervical screening? Cytojournal. 2014; 11: 14.
14. Mody DR, Krishnamurthy S, Anton R, Thrall MJ,. Diagnostic Pathology: Cytopathology. Philadelphia, PA: Lippincott Williams & Wilkins; 2014.
15. Hopenhayn C, Christian A, Christian WJ, et al., Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis. 2014; 18: 182-189.
16. Zhao C, Li Z, Nayar R, et al., Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: results of a retrospective multicenter study. Arch Pathol Lab Med. 2015; 139: 184-188.
17. Katki HA, Kinney WK, Fetterman B, et al., Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet. 2011; 12: 663-672.
18. Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS,. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015; 123: 282-288.
19. Quiroga-Garza G, Zhou H, Mody DR, Schwartz MR, Ge Y,. Unexpected high prevalence of HPV 90 infection in an underserved population: is it really a low-risk genotype? Arch Pathol Lab Med. 2013; 137: 1569-1573.
20. Austin RM, Zhao C,. Type 1 and type 2 cervical carcinomas: some cervical cancers are more difficult to prevent with screening. Cytopathology. 2012; 23: 6-12.
21. Wu Y, Chen Y, Li L, Yu G, Zhang Y, He Y,. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol. 2006; 35: 264-269.
22. Kang WD, Kim CH, Cho MK, et al., Comparison of the Hybrid Capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. Int J Gynecol Cancer. 2009; 19: 924-928.
23. Moreira MA, Longato-Filho A, Taromaru E, et al., Investigation of human papillomavirus by Hybrid Capture II in cervical carcinomas including 113 adenocarcinomas and related lesions. Int J Gynecol Cancer. 2006; 16: 586-590.
24. Poljak M, Kovanda A, Kocjan BJ, Seme K, Jancar N, Vrtacnik-Bokal E,. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol Alp Pannonica Adriat. 2009; 18: 94-103.
25. Massad LS, Einstein MH, Huh WK, et al., 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013; 121: 829-846.
26. Zhao C, Florea A, Onisko A, Austin RM,. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol. 2009; 114: 383-389.
27. Belinson J, Qiao YL, Pretorius R, et al., Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001; 83: 439-444.
28. Dudding N, Crossley J,. Sensitivity and specificity of HPV testing: what are the facts? Cytopathology. 2013; 24: 283-288.